|  |
| --- |
| ARGB Appendix 13 - Guidance on TGO 109: Standard for Biologicals |
| Australian Regulatory Guidelines for Biologicals (ARGB) |
| Version 1.0, May 2021 |

Copyright

© Commonwealth of Australia 2021  
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[tga.copyright@tga.gov.au](mailto:tga.copyright@tga.gov.au)>

Confidentiality

All submissions received will be placed on the TGA’s Internet site, unless marked confidential. Any confidential material contained within your submission should be provided under a separate cover and clearly marked “IN CONFIDENCE”. Reasons for a claim to confidentiality must be included in the space provided on the TGA submission form. For submission made by individuals, all personal details, other than your name, will be removed from your submission before it is published on the TGA’s Internet site. In addition, a list of parties making submissions will be published. If you do not wish to be identified with your submission you must specifically request this in the space provided on the submission form.

Contents

[About this guidance 5](#_Toc70672207)

[About TGO 109 5](#_Toc70672208)

[Commencement of TGO 109 6](#_Toc70672209)

[Review of TGO 109 6](#_Toc70672210)

[Guidance on the requirements of TGO 109 7](#_Toc70672211)

[Part 2 – Standard for all biologicals 7](#_Toc70672212)

[Section 8 – What this Part is about 7](#_Toc70672213)

[Section 9 – Diseases and conditions that may compromise biologicals 7](#_Toc70672214)

[Section 10 – Critical materials 9](#_Toc70672215)

[Section 11 – Microbial contamination control strategy 11](#_Toc70672216)

[Section 12 – Samples for bioburden testing 11](#_Toc70672217)

[Section 13 – Bioburden testing requirements 13](#_Toc70672218)

[Section 14 – Sterilisation 14](#_Toc70672219)

[Section 15 – Collection from deceased donors 15](#_Toc70672220)

[Section 16 – Storage and transportation: HCT materials 16](#_Toc70672221)

[Section 16 – Storage and transportation: biologicals 17](#_Toc70672222)

[Section 17 – Containers of biologicals 19](#_Toc70672223)

[Part 3 – Standard for human musculoskeletal tissue products 19](#_Toc70672224)

[Section 18 – What this Part is about 19](#_Toc70672225)

[Section 19 – Application of this Part 20](#_Toc70672226)

[Section 20 – Collection from deceased donors 20](#_Toc70672227)

[Section 21 – Bioburden testing 21](#_Toc70672228)

[Section 22 – Demineralised products 23](#_Toc70672229)

[Section 23 – Freeze-dried products 24](#_Toc70672230)

[Section 24 – Storage and transportation 24](#_Toc70672231)

[Part 4 – Standard for human cardiovascular tissue products 25](#_Toc70672232)

[Section 25 – What this Part is about 25](#_Toc70672233)

[Section 26 – Application of this Part 25](#_Toc70672234)

[Section 27 – Tissue not subjected to a bioburden reduction process 26](#_Toc70672235)

[Section 28 – Tissue subjected to a bioburden reduction process 28](#_Toc70672236)

[Section 29 – Heart valves 29](#_Toc70672237)

[Section 30 – Storage and transportation 29](#_Toc70672238)

[Part 5 – Standard for human ocular tissue products 30](#_Toc70672239)

[Section 31 – What this Part is about 30](#_Toc70672240)

[Section 32 – Application of this Part 30](#_Toc70672241)

[Section 33 – Collection 31](#_Toc70672242)

[Section 34 – Storage and transportation 32](#_Toc70672243)

[Section 35 – Excised cornea – testing of storage medium etc. 32](#_Toc70672244)

[Section 36 – Containers 33](#_Toc70672245)

[Section 37 – Examination and evaluation 34](#_Toc70672246)

[Part 6 – Standard for human skin products 34](#_Toc70672247)

[Section 38 – What this Part is about 34](#_Toc70672248)

[Section 39 – Application of this Part 35](#_Toc70672249)

[Section 40 – Processing etc. 35](#_Toc70672250)

[Section 41 – Bioburden testing 36](#_Toc70672251)

[Section 42 – Freeze-dried skin allografts 37](#_Toc70672252)

[Section 43 – Storage and transport 37](#_Toc70672253)

[Part 7 – Standard for human amnion products 38](#_Toc70672254)

[Section 44 – What this Part is about 38](#_Toc70672255)

[Section 45 – Application of this Part 38](#_Toc70672256)

[Section 46 – Collection 39](#_Toc70672257)

[Section 47 – Terminal sterilisation 39](#_Toc70672258)

[Section 48 – Dehydrated products 40](#_Toc70672259)

[Section 49 – Freeze-dried products 40](#_Toc70672260)

[Section 50 – Storage and transportation 41](#_Toc70672261)

## About this guidance

As prepared by the Therapeutic Goods Administration (TGA), this guidance describes the requirements for [manufacturers](https://www.tga.gov.au/manufacturing-therapeutic-goods) and [sponsors](https://www.tga.gov.au/role-sponsor) of biologicals in the Therapeutic Goods (Standard for Biologicals) (TGO 109) Order 2021.

Generally, [TGOs](https://www.tga.gov.au/therapeutic-goods-orders) are standards that determine the consistency of product quality, including label quality. TGO 109 specifies general manufacturing and quality requirements for therapeutic goods comprising, derived or containing human cells or tissues (HCT).

As an HCT product provider, you must comply with requirements that contribute to the quality and safety of HCT products, and that mitigate infectious disease risks.

TGO 109 replaces numerous TGOs:

* [Therapeutic Goods Order No. 83 - Standards for human musculoskeletal tissue (TGO 83)](http://www.legislation.gov.au/Series/F2011L01489)
* [Therapeutic Goods Order No. 84 - Standards for human cardiovascular tissue (TGO 84)](http://www.legislation.gov.au/Series/F2011L01490)
* [Therapeutic Goods Order No. 85 - Standards for human ocular tissue (TGO 85)](http://www.legislation.gov.au/Series/F2011L01491)
* [Therapeutic Goods Order No. 86 - Standards for human skin (TGO 86)](http://www.legislation.gov.au/Series/F2011L01492)

All these TGOs ‘sunsetted’ on 1 October 2021. Sunsetting is the process whereby legislative instruments undergo automatic repeal after 10 years following their registration.

TGO 109 also includes some aspects of this TGO:

* [Therapeutic Goods Order No. 88 - Standards for donor selection, testing, and minimising infectious disease transmission via therapeutic goods that are human blood and blood components, human tissues and human cellular therapy products (TGO 88)](https://www.legislation.gov.au/Series/F2013L00854)

TGO 88 does not sunset until 1 October 2023 but has been updated given the crossover with the product-specific TGOs 83-86.

|  |
| --- |
| This information is provided for guidance only and has been developed on the basis of current knowledge of the subject matter.  It should not be relied on to address every aspect of the relevant legislation. You should seek your own independent legal advice to ensure that all of the legislative requirements are met.  For clarification of a particular requirement, contact [TGA’s Biological Science Section (BSS)](https://www.tga.gov.au/biologicals-0#contacts). |

## About TGO 109

TGO 109 specifies minimum manufacturing and quality requirements and includes:

* general standards for:
  + all biologicals (Part 2)
* specific standards for human tissues which have only been subjected to minimal manipulation:
  + musculoskeletal products (Part 3)
  + cardiovascular products (Part 4)
  + ocular products (Part 5)
  + skin products (Part 6)
  + amniotic products (Part 7)

This guidance provides an interpretation of how the various requirements of TGO 109 can be met.

TGO 109 **applies to:**

* all biologicals (encompassing HCT materials, starting materials, intermediates and finished therapeutic goods) that come within the operation of Part 3-2A of the *Therapeutic Goods Act 1989* (the Act)

TGO 109 **does not apply to:**

* biologicals that are not intended for therapeutic use, that is, blood or tissue samples for infectious disease or bioburden testing
* exempt autologous HCT products
* faecal microbiota transplant (FMT) products
* biologicals mentioned in item 13 of Schedule 5A to the *Therapeutic Goods Regulations 1990* (the Regulations), subject to compliance with the condition specified in that item

If you are unsure whether TGO 109 applies to a specific biological, please contact TGA’s Biological Science Section (BSS) for clarification.

### Commencement of TGO 109

TGO 109 commences on 30 September 2021. Prior to this date, these TGOs applied:

* [Therapeutic Goods Order No. 83 - Standards for human musculoskeletal tissue (TGO 83)](http://www.legislation.gov.au/Series/F2011L01489)
* [Therapeutic Goods Order No. 84 - Standards for human cardiovascular tissue (TGO 84)](http://www.legislation.gov.au/Series/F2011L01490)
* [Therapeutic Goods Order No. 85 - Standards for human ocular tissue (TGO 85)](http://www.legislation.gov.au/Series/F2011L01491)
* [Therapeutic Goods Order No. 86 - Standards for human skin (TGO 86)](http://www.legislation.gov.au/Series/F2011L01492)
* [Therapeutic Goods Order No. 88 - Standards for donor selection, testing, and minimising infectious disease transmission via therapeutic goods that are human blood and blood components, human tissues and human cellular therapy products (TGO 88)](https://www.legislation.gov.au/Series/F2013L00854)

### Review of TGO 109

TGO 109 will be reviewed regularly as changes in legislation, emerging technology, and best practice occur. Sponsors and manufacturers are encouraged to discuss with TGA any proposed changes in practice or evolving technologies that may affect, or be affected by, the requirements of TGO 109.

## Guidance on the requirements of TGO 109

|  |
| --- |
| This guidance should be read in conjunction with:  Therapeutic Goods (Standard for Biologicals) (TGO 109) Order 2021 |

### Part 2 – Standard for all biologicals

#### Section 8 – What this Part is about

|  |
| --- |
| **8 What this Part is about**  This Part specifies general requirements that must be met in the manufacture of all biologicals, including requirements relating to the HCT materials used in the manufacture of those biologicals.  Unless otherwise specified, the requirements in this Part apply to all biologicals, including a biological that is subject to a specific standard in Parts 3 to 7 of this instrument. |

This section specifies general requirements that must be met in the manufacture of all biologicals, including requirements relating to the HCT materials (includes HCT that are collected and/or in various stages of processing for manufacture of the biological) used in the manufacture of those biologicals.

#### Section 9 – Diseases and conditions that may compromise biologicals

|  |
| --- |
| **9 Diseases and conditions that may compromise biologicals**  A biological must not be manufactured using HCT materials collected from a donor who is known to have a disease or condition that may compromise the quality, safety or efficacy of the biological, unless:   1. criteria for donor selection and periods of donor ineligibility, based on validated data or documented evidence from relevant scientific literature, are applied that support and justify the quality, safety and efficacy of the biological, and the application of the criteria is documented; or 2. in any case where it is not possible to comply with paragraph (a)—a registered medical practitioner acting for or on behalf of the manufacturer or the sponsor has agreed to, and documented the rationale for, the use of the HCT materials in the manufacture of the biological. |

This section recognises that diseases and pathological conditions, including those specified in TGO 108 (that is, infectious diseases), might affect the quality, safety or efficacy of the biological. These include donor age or medical treatment prior to collection that may adversely affect the quality of the HCT material or the biological. The criteria would depend on the type and the intended use of the biological such as:

• tissues exposed to irradiation

• diseases that affect joint integrity in musculoskeletal donors

• immunodeficiency disorders or the use of immunosuppressive agents in patients with a consequent higher risk of asymptomatic opportunistic infection

• reactivation of past infection

• situations that could impair the ability of testing to detect infection, for example, hypogammaglobulinaemia, HCV antibody testing

These requirements allow for the manufacturer to specify additional criteria that may be applicable based on clinical justification. Manufacturers must ensure that relevant deferral criteria are communicated to organisations conducting the collection process, to ensure donors are screened for these criteria before acceptance of the starting material.

Manufacturers should consult relevant tissue-specific chapters of the Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides) to establish an initial list of conditions that should result in deferral or rejection of donors of specific tissue types. These lists are not exhaustive, and the manufacturer should conduct their own risk assessment to develop and maintain donor selection criteria based on their HCT product and manufacturing process.

Compliance with this section will also consider compliance with TGO 108, along with other considerations that are not just infectious diseases. Justification for the selection and evaluation of disease and conditions should be included in submitted dossier.

A registered medical practitioner may accept donors with underlying disease or conditions if they have performed an adequate risk assessment/have an adequate rationale taking into account the intended use of the HCT product and the intended recipient. The justification/risk assessment should appear in the relevant section of the dossier.

#### Section 10 – Critical materials

|  |
| --- |
| **10 Critical materials**   1. The critical materials used in the manufacture of a biological must: 2. not be contaminated with, or be likely to introduce, microorganisms or other infectious disease agents; and 3. not adversely affect the quality, safety or efficacy of the biological; and 4. where the critical materials are solutions that come into contact with HCT materials or biologicals (other than critical materials mentioned in paragraph (d))—be manufactured under an approved quality management system and either: 5. be supplied as a sterile solution; or 6. satisfy sterility requirements specified in an applicable standard; and 7. where the critical materials are non-sterile antimicrobial agents used in a bioburden reduction process for HCT materials—be passed through a 0.22µm filter prior to use in the bioburden reduction process; and 8. where the critical materials are of human or animal origin (other than HCT materials)—meet the requirements set out in: 9. the TGA Approach to TSE; and 10. the Guidance on Virus Validation Studies.   *Critical materials not included in the Register*   1. The following information in relation to critical materials that are not included in the Register must be available and documented: 2. screening tests performed and quality control specifications, including criteria and limits for tests; and 3. storage conditions. |

A manufacturer is not necessarily required to perform testing on critical materials to ensure they are not contaminated with or likely to introduce bacterial or other infectious agents. Selection and evaluation of a critical material could be via documents provided by the material manufacturer or of testing performed by the manufacturer, to demonstrate suitability.

Justification of the selection and evaluation of critical material should be included in submitted dossier.

This clause ensures that the manufacturer considers the quality of all materials that come into contact with the product. This includes from the time of collection through to the final packaging. The clause is also designed to ensure that these materials will not adversely affect the quality, safety and efficacy of the final product. Similar clauses had been previously included in all tissue-specific TGOs. Provision of a list of critical materials is usually included in the dossier for review.

Critical materials include all supplies and reagents that come into direct contact with the staring material or product during any stage of manufacture, including primary containers and collection kits. Equipment used in the manufacturing process of HCT products that does not come into direct contact with the product is not a critical material, for example, centrifuges.

To ensure the suitability of critical materials, you should review:

* material specifications provided by the material supplier

OR

* testing performed by the manufacturer, to demonstrate suitability

If material specifications are not provided, or the documents do not provide sufficient evidence, you may need to perform testing on critical materials to ensure they are suitable for use and not contaminated with, or likely to introduce, endotoxin, bacteria, or other infectious agents.

You will need to justify the suitability of all critical materials used in the collection, manufacture, storage and release of the HCT product. If any of the critical materials are included in the [Australian Register of Therapeutic Goods (ARTG)](https://www.tga.gov.au/australian-register-therapeutic-goods), then you:

* can cross-reference the ARTG number
* do not need to resubmit validation data for reassessment
* should include a statement justifying that the critical material is being used for the same purpose for which it is registered and that it meets sterility requirements

Selection and evaluation of a critical material can include documents provided by the material manufacturer or suitability testing performed by the manufacturer. Justification of the selection and evaluation of critical material should be included in the submitted dossier.

Manufacturers need to determine what requirements are applicable to critical solutions. The pharmacopoeial test for sterility is currently the test as specified in the default standards under Part 3.1 of the TG Act, namely, the British Pharmacopoeia, the European Pharmacopoeia, or the United States Pharmacopeia. A filter integrity test should be performed on the filters used to sterilise solutions. It is necessary to verify that the sterilising filter is compatible with antimicrobial solutions.

Critical materials derived from human and animal sources present a unique risk for the potential transmission of viruses and Transmissible Spongiform Encephalopathy (TSE) agents. These materials must be sourced, tested (if methodology is available), and assessed as presenting a minimal risk of transmitting infectious disease agents in accordance with the requirements set out in the following documents:

* TGA guidance: [Transmissible Spongiform Encephalopathies (TSE): TGA approach to minimising the risk of exposure](https://www.tga.gov.au/transmissible-spongiform-encephalopathies-tse-tga-approach-minimising-risk-exposure)
* European Medicine Agency (EMA) guidance: [Note for Guidance on Virus Validation Studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses](https://www.ema.europa.eu/en/virus-validation-studies-design-contribution-interpretation-studies-validating-inactivation-removal)

Where equipment and containers are in direct contact with the starting material, they should be sterile and/or single-use. If reusable equipment and containers are used, they are subject to validation. Cleaning and sterilisation processes should be monitored to minimise risk of cross-contamination.

#### Section 11 – Microbial contamination control strategy

|  |
| --- |
| **11 Microbial contamination control strategy**  A risk-based microbial contamination control strategy, which considers the nature of HCT materials and biologicals, must:   1. be implemented to minimise intrinsic and extrinsic microbial contamination of HCT materials and biologicals; and 2. specify storage, handling and transportation requirements (including in relation to temperature and duration) for the HCT materials and biologicals. |

This section mandates that the strategies to minimise microbial contamination must be maintained and may depend on the specific processing and uses of the biological. It is acknowledged that some starting materials (HCT materials) are not sterile as they have inherent microflora that will not be eradicated by processing or manufacturing steps. The microbiological specifications for these finished products should be formulated to specify the maximum allowable level and specify the absence of ‘specified microorganisms’, which would render the product unsuitable for use.

#### Section 12 – Samples for bioburden testing

|  |
| --- |
| **12 Samples for bioburden testing**   1. Samples must be taken for bioburden testing. 2. Samples must be: 3. taken using a validated sampling technique; and 4. tested using a validated test method.   Note: Subsections (1) and (2) apply in relation to all biologicals, other than human ocular tissue products to which Part 5 applies.   1. This section does not apply in relation to human ocular tissue products to which Part 5 applies.   Note: Part 5 specifies bioburden testing requirements in relation to human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsections (1) and (2) apply in relation to all other human ocular tissue products. |

Bioburden sampling and testing must occur using validated techniques or testing methods.

Both the sampling method and the bioburden test method must be validated, the details of which should be included in the relevant section of the dossier. Unless the entire tissue product is subject to bioburden testing, it is necessary to validate that a sample or portion is representative of the entire tissue. During sampling validation studies, it is necessary to sample from a variety of areas across the tissue and to compare the bioburden test results. Routine bioburden samples should subsequently be taken from any area which represents the ‘worst case’ in terms of bioburden.

The microbial contamination sections of the pharmacopoeial default standards,[[1]](#footnote-1) as well as ISO/DTS 22456[[2]](#footnote-2) and ISO 14160,[[3]](#footnote-3) provide useful guidance on suitable bioburden test methods and their validation to demonstrate neutralisation/inactivation of antimicrobial substances. ISO 11737-1 specifically describes steps to establish the recovery efficiency and correction factor(s) that are to be applied when testing bioburden on/within solid and semi-solid starting materials (for example, bone, tendon).

#### Section 13 – Bioburden testing requirements

|  |
| --- |
| **13 Bioburden testing requirements**   1. Written specifications for HCT materials and biologicals must include specified microorganisms determined on the basis of a risk assessment. 2. Samples must demonstrate that HCT materials are free from contamination with specified microorganisms. 3. Samples must demonstrate that biologicals are: 4. free from microbial contamination; or 5. if, on the basis of a risk assessment, it is not necessary for the biological to be free from microbial contamination—free from contamination with specified microorganisms. 6. This section does not apply in relation to: 7. human cardiovascular tissue products to which Part 4 applies; and 8. human ocular tissue products to which Part 5 applies.   Note 1: Part 4 provides that human cardiovascular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only, and human cardiovascular tissue used in the manufacture of those products, must be free from microbial contamination. However, this section applies in relation to all other human cardiovascular tissue products.  Note 2: Part 5 specifies bioburden testing requirements in relation to human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, this section applies in relation to all other human ocular tissue products.   1. Subsection (3) does not apply in relation to: 2. human musculoskeletal tissue products to which Part 3 applies; and 3. human skin products to which Part 6 applies.   Note 1: Part 3 provides that human musculoskeletal tissue products that are subjected to only minimal manipulation must be free from microbial contamination, and human musculoskeletal tissue used in the manufacture of those products must be free from contamination with specified microorganisms. However, subsection (3) applies in relation to all other human musculoskeletal tissue products.  Note 2: Part 6 provides that human skin products that are subjected to only minimal manipulation and human skin used in the manufacture of those products must be free from contamination with specified microorganisms. However, subsection (3) applies in relation to all other human skin products. |

This section applies to any HCT material (collected or during processing) and the finished product (biological). In order to show the absence of microorganisms or specified microorganisms, the biological must be sampled and tested using validated methods, the details of which should be included in the relevant section of the dossier.

Sponsors must develop a documented list with all relevant microorganisms that, if present, would result in a rejection of the product.

The manufacturer should use a risk-based approach to develop the list of specified microorganisms of clinical significance for the product, which, if isolated, require rejection of the tissue for clinical use. This process should include consideration of the category of HCT, the method of processing, and the nature and type of microorganisms which might be present. The list of microorganisms should be detailed in the appropriate dossier section. The Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides) provides guidance around microbial contaminants that should result in tissue discard, although these lists are not exhaustive.[[4]](#footnote-4) Sponsors should provide their own specified microorganisms and justification.

There are two possible outcomes for the HCT material which demonstrates microbial contamination. Either:

* the HCT material or biological must be deemed unsuitable for therapeutic use

OR

* provided that specified microbes are excluded, the HCT material or biological may be processed or released

When a bioburden reduction treatment renders a biological ‘free from microbial contamination’, then that biological is not regarded as sterile unless the process was validated as a sterilisation process and the product passes a pharmacopoeial sterility test.

The microbial contamination sections of the pharmacopoeial default standards,[[5]](#footnote-5) as well as ISO/DTS 22456[[6]](#footnote-6) and ISO 14160,[[7]](#footnote-7) provide useful guidance on suitable bioburden test methods and their validation to demonstrate neutralisation/inactivation of antimicrobial substances. ISO 11737-1 specifically describes steps to establish the recovery efficiency and correction factor(s) that are to be applied when testing bioburden on/within solid and semi-solid starting materials (for example, bone, tendon).

#### Section 14 – Sterilisation

|  |
| --- |
| **14 Sterilisation**  The sterilisation process for a biological that is terminally sterilised must be validated to ensure a maximal sterility assurance level of 10-6. |

If the product is to be terminally sterilised, then validation and routine control of sterilisation processes should be in accordance with the relevant parts of international sterilisation standards, for example, ISO 11135 (ethylene oxide), ISO 14937 (general methods), ISO 17665 (moist heat), ISO 11137 (radiation), ISO 14160 (chemical sterilisation), ISO 20857 (dry heat).

Some of these standards are relevant to the sterilisation of containers and ancillary materials used during tissue processing.

All containers should be sterile and any of the ISO standards listed above provide guidance for validating the relevant sterilisation process for containers. Containers can also be pre-purchased as sterile.

#### Section 15 – Collection from deceased donors

|  |
| --- |
| **15 Collection from deceased donors**   1. HCT materials must be collected from a deceased donor as soon as possible after asystole, and collection must be completed: 2. if the body has been refrigerated below 10°C within 12 hours of asystole—not later than 24 hours after asystole; or 3. if paragraph (a) does not apply—not later than 15 hours after asystole. 4. This section does not apply in relation to: 5. human musculoskeletal tissue products to which Part 3 applies; and 6. human ocular tissue products to which Part 5 applies; and 7. human amnion products to which Part 7 applies.   Note 1: Part 3 provides requirements in relation to the collection of human musculoskeletal tissue used in the manufacture of human musculoskeletal tissue products that are subjected to only minimal manipulation. However, this section applies in relation to all other human musculoskeletal tissue products.  Note 2: Part 5 provides requirements in relation to the collection of human ocular tissue used in the manufacture of human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, this section applies in relation to all other human ocular tissue products.  Note 3: Part 7 provides requirements in relation to the collection of human amnion used in the manufacture of human amnion products that are subjected to only minimal manipulation. However, this section applies in relation to all other human amnion products. |

When collecting HCT material from deceased donors, the time between asystole and the commencement of the collection process must be as small as possible to minimise the proliferation of microbial contaminants. The timeframes detailed in this clause are the default collection timeframes. Specific tissue types may have more stringent or more relaxed collection criteria defined in Parts 3-7 of TGO 109. If collection timeframes are longer than those defined above, the quality of the starting material must be validated to demonstrate that extending the time before collection does not compromise the quality, safety or efficacy of the HCT product manufactured from the starting material.

#### Section 16 – Storage and transportation: HCT materials

|  |
| --- |
| **16 Storage and transportation**  *HCT materials*   1. Immediately following collection and prior to processing, HCT materials must be: 2. stored as follows: 3. at less than 10°C for not longer than 72 hours; or 4. as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the biological manufactured using the HCT materials; and 5. transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation. 6. Subsection (1) does not apply in relation to: 7. human cardiovascular tissue products to which Part 4 applies; and 8. human skin products to which Part 6 applies 9. human amnion products to which Part 7 applies.   Note 1: Part 4 provides storage and transportation requirements in relation to cardiovascular tissue used in the manufacture of cardiovascular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsection (1) applies in relation to all other human cardiovascular tissue products.  Note 2: Part 6 provides storage and transportation requirements in relation to human skin used in the manufacture of human skin products that are subjected to only minimal manipulation. However, subsection (1) applies in relation to all other human skin products.  Note 3: Part 7 provides storage and transportation requirements in relation to human amnion used in the manufacture of human amnion products that are subjected to only minimal manipulation. However, subsection (1) applies in relation to all other human amnion products.   1. HCT materials that are collected and transported for use in the manufacture of a biological must be packaged using aseptic technique and with at least one moisture impermeable barrier. |

This section provides a default temperature and time between the collection of starting material and commencement of processing. Timeframes outside of these parameters must be validated to demonstrate that the starting material (HCT material) quality is not affected, especially with respect to proliferation of microbial bioburden. Unless alternative timeframes have been defined in Parts 3-7 of TGO 109, the default collection to processing timeframe should be less than 72 hours, with the starting material stored below 10°C.

The collected starting material may be stored before the commencement of processing, but this clause mandates that the manufacturer has validated the proposed pre-processing storage conditions.

If longer pre-processing storage or higher storage temperatures are used, the manufacturer must provide data to demonstrate that the quality and safety of the biological will not be adversely affected. Validation data should demonstrate that the HCT product manufactured from stored starting material is capable of meeting all product release specifications. This data should also be used to inform process control points that provide limits to pre-processing storage times.

#### Section 16 – Storage and transportation: biologicals

|  |
| --- |
| **16 Storage and transportation**  *Biologicals*   1. Biologicals must be stored and transported under conditions that are validated, including justified time and temperature specifications, to ensure the quality and safety of the biologicals. 2. Subsection (4) does not apply in relation to: 3. human musculoskeletal tissue products to which Part 3 applies; and 4. human cardiovascular tissue products to which Part 4 applies; and 5. human ocular tissue products to which Part 5 applies; and 6. human skin products to which Part 6 applies; and 7. human amnion products to which Part 7 applies.   Note 1: Part 3 provides storage and transportation requirements in relation to human musculoskeletal tissue products that are subjected to only minimal manipulation. However, subsection (4) applies in relation to all other human musculoskeletal tissue products.  Note 2: Part 4 provides storage and transportation requirements in relation to human cardiovascular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsection (4) applies in relation to all other human cardiovascular tissue products.  Note 3: Part 5 provides storage and transportation requirements in relation to human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsection (4) applies in relation to all other human ocular tissue products.  Note 4: Part 6 provides storage and transportation requirements in relation to human skin products that are subjected to only minimal manipulation. However subsection (4) applies in relation to all other human skin products.  Note 5: Part 7 provides storage and transportation requirements in relation to human amnion products that are subjected to only minimal manipulation. However, subsection (4) applies in relation to all other human amnion products.   1. A biological that is returned to its manufacturer cannot be released for supply unless: 2. the biological was at all times stored and transported in accordance with applicable storage and transportation requirements in relation to the biological; and 3. the labelling and packaging of the biological has not been compromised. |

The manufacturer must validate the storage conditions of the HCT product (that is, the biological) to ensure that the quality is not compromised.

The purpose of this clause is to ensure that the manufacturer has validated the shelf life and storage conditions of the final product. Tissue-specific parts provide ‘default’ shelf life based on international best practise for different tissue types. This clause captures the same requirement for all other biological products.

The manufacturer must provide data demonstrating that the shelf life, as defined by proposed storage conditions and times, maintains the quality and safety of the HCT product. Critical quality parameters must be measured for at least three batches of product at regular intervals to confirm that product quality is maintained. Integrity and suitability of the container systems must also be demonstrated for the proposed storage conditions and shelf life.

A biological that has undergone a deviation to the recommended storage conditions may only be supplied if TGA has assessed the data to support the release. This data may be submitted in the original application, or as a variation to the proposed shelf life. Any deviations from proposed storage conditions (for example, temperature excursions, thermal cycling) must be validated using at least three batches of the product.

The following guidance (for prescription medicines) may be of use in evaluating the shelf life of a biological product and for the design of stability studies for your HCT product:

* TGA guidance: [Stability testing for prescription medicines](https://www.tga.gov.au/sites/default/files/stability-testing-prescription-medicines.pdf)
* EMA guidance: [Quality of biotechnological products: Stability Testing of Biotechnological/Biological Products](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-topic-q-5-c-quality-biotechnological-products-stability-testing-biotechnological/biological-products_en.pdf)

This section ensures that the manufacturer has procedures in place to actively monitor, or has validated, the transportation of the allograft after release to ensure that storage conditions are maintained.

Allowance has been made for manufacturers to justify and set their own transport and storage temperature requirements after processing (unless defined in Parts 3-7 of TGO 109). The conditions of product transport and storage should be specified to ensure maintenance of product quality including minimisation of microbial contamination. Active monitoring of product temperature and conditions may be conducted following release of product. Alternatively, the transportation process should be validated, and limited to validated temperatures and timeframes.

If the manufacturer intends to accept returns of biological, they must have a documented system in place to ensure that the quality, safety and efficacy of the biological has not been compromised between release and return. This includes procedures to ensure that the product has been stored at the required temperatures at all times following release, or has only been exposed to temperature excursions that have been demonstrated (through validation studies) to not compromise product quality. These procedures will need to be provided to TGA for review in the dossier.

#### Section 17 – Containers of biologicals

|  |
| --- |
| **17 Containers of biologicals**   1. A biological must be sealed within a sterile container and must be at least double packaged so as to: 2. prevent ingress or egress of all materials; and 3. ensure that any breach of integrity of the container and packaging is evident. 4. This section does not apply in relation to human ocular tissue products to which Part 5 applies.   Note: Part 5 provides requirements in relation to containers of human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, this section applies in relation to all other human ocular tissue products. |

The sterile packaging should be compatible with the product and if terminally sterilised, with the method of sterilisation, for example, the packaging should allow the ingress of the sterilising agent and where applicable, its egress. It is permissible to sterilise the container along with the HCT. The use of new technology (for example, supercritical CO2) would be considered on a case-by-case basis based on evidence of validation to demonstrate that there is a maximal sterility assurance level (SAL) of 10-6 for a terminal sterilisation process. Guidance on novel sterilisation method validation can be found in ISO 14937.

If the tissue is aseptically manufactured, then it should be transferred into a sterile container and validated as an aseptic process (refer to ISO 13408 and ISO 18362).

### Part 3 – Standard for human musculoskeletal tissue products

#### Section 18 – What this Part is about

|  |
| --- |
| **18 What this Part is about**  This Part specifies requirements that must be met in the manufacture of human musculoskeletal tissue products that have been subjected to only minimal manipulation, including requirements relating to human musculoskeletal tissue that is collected for use in the manufacture of those products.  Unless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part. |

Part 3 applies to human musculoskeletal tissue including muscle, ligament, tendon, fascia lata, bone or cartilage.

#### Section 19 – Application of this Part

|  |
| --- |
| **19 Application of this Part**  This Part applies in relation to human musculoskeletal tissue products that have been subjected to only minimal manipulation. |

Minimal manipulation is defined by TGA here:

* TGA guidance: [Method of preparation: Interpretation of minimal manipulation](https://www.tga.gov.au/sites/default/files/method-preparation-interpretation-minimal-manipulation.pdf)

#### Section 20 – Collection from deceased donors

|  |
| --- |
| **20 Collection from deceased donors**   1. The collection of human musculoskeletal tissue from a deceased donor must commence as soon as possible after asystole and: 2. if the body has been refrigerated below 10°C within 12 hours after asystole—not later than 24 hours after asystole; or 3. if paragraph (a) does not apply—not later than 15 hours after asystole. 4. The collection of human musculoskeletal tissue from a deceased donor must be completed within 36 hours after asystole. |

Collection of musculoskeletal tissue should commence as soon as possible after asystole with the maximum allowable time for completion of the collection being 36 hours. The time post-asystole at which the collection of musculoskeletal tissue must commence is dependent on the temperature at which the body has been stored: if it has been refrigerated below 10°C within 12 hours of asystole, then collection must commence within 24 hours; otherwise, collection must commence within 15 hours.

The application of antiseptic solution to decontaminate the donor’s skin (skin preparation) is generally accepted as the commencement of the collection process as defined in the [American Association for Tissue Banks (AATB) guidance](https://www.aatb.org/standards/guidance-documents).


#### Section 21 – Bioburden testing

|  |
| --- |
| **21 Bioburden testing**  *Tissue not subjected to processing*   1. Human musculoskeletal tissue that is not subjected to processing prior to packaging must be sampled at the time of collection for bioburden testing. 2. Human musculoskeletal tissue sampled in accordance with subsection (1) must be tested for bioburden and: 3. demonstrate no microbial contamination; or 4. be rejected for therapeutic use if microbial contamination is demonstrated; or 5. be subjected to further processing in accordance with subsection (3) if microbial contamination is demonstrated with microorganisms other than specified microorganisms.   *Tissue subjected to processing*   1. Human musculoskeletal tissue that is subjected to processing prior to packaging (including, for example, a bioburden reduction process) must be: 2. sampled for bioburden testing at the time of collection or prior to the processing to exclude tissue contaminated with specified microorganisms; and 3. either: 4. sampled for bioburden testing after the processing and must demonstrate no microbial contamination; or 5. subjected to a bioburden reduction process that has been validated to render the tissue free from any microbial contamination. 6. Human musculoskeletal tissue that demonstrates: 7. contamination with specified microorganisms when tested in accordance with paragraph 21(3)(a); or 8. any microbial contamination when tested in accordance with subparagraph 21(3)(b)(i);   must not be used for therapeutic use. |

For musculoskeletal tissue that is not to be processed after collection, the tissue must be sampled for bioburden at the time of collection and subsequently shown to be free of microbial contamination. Both the sampling method and the bioburden test method must be validated, the details of which should be included in the relevant section of the dossier.

The flowchart in Figure 1 shows how the requirements identified in this section establish the suitability of the collected musculoskeletal tissue for therapeutic use.

Figure 1 – Flowchart for musculoskeletal tissue.



There are two possible outcomes for collected and sampled musculoskeletal tissue which demonstrates microbial contamination. Either the tissue must be:

* deemed unsuitable for therapeutic use

OR

* provided that specified microbes are excluded (see Part 2), the tissue can be subject to further processing to render it free from microbial contamination (as detailed in Part 3)

Tissue should be sampled at the time of collection for bioburden, and when contaminated with specified microorganisms (see Part 2), the tissue should be excluded from therapeutic use. If not contaminated with specified microorganisms, the tissue should be either:

* sampled post-bioburden reduction and demonstrate no microbial contamination

OR

* subjected to a bioburden reduction process that has been validated to render the tissue free from microbial contamination

For guidance on the validation of bioburden sampling method and validation of bioburden test method, see Part 2.

When a bioburden reduction treatment renders a tissue ‘free from microbial contamination’, the tissue is not regarded as sterile unless the process was validated as a sterilisation process and the product passes a pharmacopoeial sterility test.

Pharmacopoieal and ISO standards for bioburden test methods include a requirement to validate the methods. This involves challenging the method used for the material or product with low numbers (< 100 CFU) of reference challenge microorganisms and recovering these organisms within the shortest test incubation time. Given that antimicrobial agents could be present in the starting materials and/or the end HCT product, it is necessary to attempt to neutralise these agents to optimise the recovery of the challenge microorganisms, and ultimately, any product contaminants. Pharmacopoeial and ISO methods mandate this step under ‘suitability of test method’ or ‘method validation’. Antimicrobial activity can often be removed by filtration, dilution and/or chemical inactivation through the use of a suitable neutralising agent. Tissue banks should attempt to identify antimicrobial agents used to treat donors and those agents used during processing in order to assist them to identify suitable neutralising agents. If antimicrobial properties cannot ultimately be neutralised, pharmacopoeias permit the product to be tested under the set of conditions established as optimal for recovery. This approach must be justified and details provided for assessment and/or audit by TGA.

If any musculoskeletal tissue demonstrates contamination of **specified** microorganisms post-collection, then this tissue must not be used for therapeutic use. Additionally, where **any** microbial contamination is detected post-processing, the tissue must not be used for therapeutic use.

#### Section 22 – Demineralised products

|  |
| --- |
| **22 Demineralised products**  The residual calcium of human musculoskeletal tissue products that are demineralised must not exceed 8% w/w. |

This is a new requirement. For a bone product to be classified as demineralised, it must have a reduction in calcium levels. This specification is adopted from the [American Association for Tissue Banks (AATB) guidance](https://www.aatb.org/standards/guidance-documents) which mandates residual calcium levels for demineralised bone products.

Unless bone is treated by a validated process to reduce minerals, representative samples of each lot shall be tested for residual calcium using a standard method. Residual calcium content for bone labelled as ‘demineralised’ shall not exceed 8% w/w according to a standard method. For bone that has been subjected to a demineralisation process with a residual calcium content target that exceeds 8% w/w when tested, the tissue must not be labelled as ‘demineralised’ and should be labelled as ‘partially demineralised’ to describe the extent of demineralisation.

Some demineralised bone may claim osteoinductive properties. An osteoinductive claim should not be made unless the osteoinductive potential of the product has been demonstrated by a validated test method. This ensures all HCT products which claim osteoinductivity have data demonstrating this biological characteristic.

#### Section 23 – Freeze-dried products

|  |
| --- |
| **23 Freeze-dried products**  The residual moisture content of human musculoskeletal tissue products that are freeze-dried must not exceed 6% w/w. |

This is a new requirement. Freeze-drying results in a decrease in the water content of the product. For a product to be labelled as ‘freeze-dried’, it must have a residual moisture content of ≤6% w/w. Freeze-drying is also known as lyophilisation and involves decreasing the water content of tissue, usually under vacuum through sublimation. Freeze-dried products are able to be stored at room temperature. This specification has been adopted from the Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides) and current dossiers for freeze-dried products.

#### Section 24 – Storage and transportation

|  |
| --- |
| **24 Storage and transportation**  Human musculoskeletal tissue products must be:   1. stored as follows: 2. at minus 20°C to minus 40°C for not more than 6 months after the collection of the human musculoskeletal tissue; or 3. frozen or cryopreserved at less than minus 40°C for not more than 5 years after the collection of the human musculoskeletal tissue; or 4. if the products are freeze-dried—at room temperature for not more than 5 years after the collection of the human musculoskeletal tissue; or 5. in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products; and 6. transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation. |

Because the storage conditions for musculoskeletal tissue are stated in TGO 109, validation of these storage conditions is not required, although validation of shelf life for packaging materials still needs to be performed. The conditions of product storage should be specified to ensure maintenance of product quality, including the minimisation of microbial contamination.

If a sponsor wishes to have an extended shelf life, the sponsor must perform validation studies.

Please note that in addition to TGO 109 requirements, all relevant requirements of TGO 107 (labelling of biologicals) apply to musculoskeletal tissue. If further clarification is required, please contact TGA.

### Part 4 – Standard for human cardiovascular tissue products

#### Section 25 – What this Part is about

|  |
| --- |
| **25 What this Part is about**  This Part specifies requirements that must be met in the manufacture of human cardiovascular tissue products that have been subjected to only minimal manipulation and are manufactured for allogeneic use only, including requirements relating to human cardiovascular tissue that is collected for use in the manufacture of those products.  Unless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part. |

Part 4 applies to human cardiovascular tissue including aortic, pulmonary, mitral and tricuspid heart valves, or any part of such valves and vascular tissue (for example, conduit or greater vessel graft, peripheral vascular tissue graft, pericardial graft).

#### Section 26 – Application of this Part

|  |
| --- |
| **26 Application of this Part**  This Part applies in relation to human cardiovascular tissue products that:   1. have been subjected to only minimal manipulation; and 2. are manufactured for allogeneic use only. |

Minimal manipulation is defined by TGA here:

* TGA guidance: [Method of preparation: Interpretation of minimal manipulation](https://www.tga.gov.au/sites/default/files/method-preparation-interpretation-minimal-manipulation.pdf)

Allogeneic use, in relation to an HCT product, means administration to, or application in the treatment of, a person other than the person from whom the HCT materials used in the manufacture of the product were collected.


#### Section 27 – Tissue not subjected to a bioburden reduction process

|  |
| --- |
| **27 Tissue not subjected to a bioburden reduction process**   1. Human cardiovascular tissue that is not subjected to a bioburden reduction process must be collected, subjected to any processing prior to packaging, sampled for bioburden testing, packaged in an operating theatre, transported to a manufacturing site, and cryopreserved. 2. The cryopreservation of human cardiovascular tissue mentioned in subsection (1) must commence: 3. in the case of a deceased donor—within 48 hours of asystole; or 4. in the case of a living donor—within 48 hours of collection. 5. Human cardiovascular tissue that is sampled in accordance with subsection (1) must be tested for bioburden and, following that testing, must: 6. demonstrate no microbial contamination; or 7. be rejected for therapeutic use if microbial contamination is demonstrated. |

This section applies to cardiovascular tissue that will not be subject to a bioburden reduction process. When this applies, the time from collection from a living donor or asystole of a deceased donor, to the commencement of cryopreservation of the packaged allograft tissue, must be less than 48 hours.

The flowchart in Figure 2 shows how the requirements identified in this section and Part 4 establish the suitability of the collected cardiovascular tissue for therapeutic use.

Figure 2 – Flowchart for cardiovascular tissue.



Unless the entire tissue product is subject to bioburden testing, it is necessary to validate that a sample or portion is representative of the entire tissue. During sampling validation studies, it is necessary to sample from a variety of areas across the tissue and to compare the bioburden test results. Routine bioburden samples should subsequently be taken from any area which represents the ‘worst case’ in terms of bioburden.

The microbial contamination sections of the pharmacopoeial default standards,[[8]](#footnote-8) as well as ISO/DTS 22456[[9]](#footnote-9) and ISO 14160,[[10]](#footnote-10) provide useful guidance on suitable bioburden test methods and their validation to demonstrate neutralisation/inactivation of antimicrobial substances. ISO 11737-1 specifically describes steps to establish the recovery efficiency and correction factor(s) to be applied when testing bioburden on or within solid and semi-solid starting materials (for example, bone, tendon).

Pharmacopoeial and ISO standards for bioburden test methods include a requirement to validate the methods. This involves challenging the method used for the material or product with low numbers (< 100 CFU) of reference challenge microorganisms and recovering these organisms within the shortest test incubation time. Given that antimicrobial agents could be present in the starting materials and/or the end HCT product, it is necessary to attempt to neutralise these agents to optimise the recovery of the challenge microorganisms, and ultimately, any product contaminants. Pharmacopoeial and ISO methods mandate this step under ‘suitability of test method’ or ‘method validation’. Antimicrobial activity can often be removed by filtration, dilution and/or chemical inactivation through the use of a suitable neutralising agent. Tissue banks should attempt to identify antimicrobial agents used to treat donors and those agents used during processing in order to assist them to identify suitable neutralising agents. If antimicrobial properties cannot ultimately be neutralised, pharmacopoeias permit the product to be tested under the set of conditions established as optimal for recovery. This approach must be justified and details provided for assessment and/or audit by TGA.

If bioburden test results fall outside the product specifications, then the tissue product should be rejected. However, if there is an urgent clinical need to use out-of-specification tissue products, then release of the product for use depends on a risk-benefit assessment. The criteria used to inform this decision should be documented. TGA must be notified of all products released which do not meet the standards set out in this order.

#### Section 28 – Tissue subjected to a bioburden reduction process

|  |
| --- |
| **28 Tissue subjected to a bioburden reduction process**   1. Human cardiovascular tissue that is subjected to a bioburden reduction process must be processed and treated with antimicrobial agents in accordance with subsections (2) and (3). 2. The processing and treatment with antimicrobial agents must commence: 3. in the case of a deceased donor—within 36 hours of asystole; or 4. in the case of a living donor—within 36 hours of collection. 5. The human cardiovascular tissue must be exposed, between dissection of the tissue from its surrounding tissue and the time of its cryopreservation, to conditions of antimicrobial treatment at: 6. 34°C to 39°C for 6 to 12 hours; or 7. 2°C to 8°C for 18 to 24 hours. 8. Following the bioburden reduction process and before the addition of cryopreservative, human cardiovascular tissue must be sampled, and tested for bioburden and, following testing, must: 9. demonstrate no microbial contamination; or 10. be rejected for therapeutic use if microbial contamination is demonstrated. |

This section applies to cardiovascular tissue that will be subject to a bioburden reduction process. When this applies, the time from collection from a donor to the treatment of antimicrobial agents must commence within 36 hours.

The flowchart in Figure 2 shows how the requirements identified in this section and Part 4 establishes the suitability of the collected cardiovascular tissue for therapeutic use. See Part 2 for guidance on bioburden sampling and method validation (including neutralisation).

The Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides) recommends that the entire manufacturing process (completion of cryopreservation) should be completed within 72 hours of asystole. Manufacturing timeframes longer than this should be justified and validated to ensure that the quality and safety of the allograft tissue is not adversely affected.

#### Section 29 – Heart valves

|  |
| --- |
| **29 Heart valves**  Human cardiovascular tissue that is a heart valve must be a competent valve prior to cryopreservation. |

The tests for heart valve competency must be detailed, and the choice of method(s) justified.

#### Section 30 – Storage and transportation

|  |
| --- |
| **30 Storage and transportation**  *Human cardiovascular tissue*   1. Immediately following collection and prior to processing in accordance with either section 27 or 28, human cardiovascular tissue must be: 2. stored as follows: 3. temperature between 0°C to 10°C; or 4. as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human cardiovascular tissue product manufactured using the tissue; and 5. transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.   *Human cardiovascular tissue products*   1. Human cardiovascular tissue products that are cryopreserved must be stored as follows: 2. at or below minus 100°C for not more than 5 years after collection of the human cardiovascular tissue; or 3. in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products. 4. Human cardiovascular tissue products that are cryopreserved must be transported in a manner that ensures the relevant storage conditions specified in subsection (2) are maintained during transportation. |

This section provides a default temperature for cardiovascular tissue storage between the collection of starting material and commencement of processing. Temperatures outside of these parameters must be validated to demonstrate that the starting material quality is not affected, especially with respect to proliferation of microbial bioburden.

If longer pre-processing storage or higher storage temperatures are used, the manufacturer must provide data to demonstrate that the quality and safety of the final HCT product will not be adversely affected. Validation data should demonstrate that the HCT product manufactured from stored starting material is capable of meeting all product release specifications. This data should also be used to inform process control points that provide limits to pre-processing storage times.

The manufacturer must validate the storage conditions of the HCT product during the manufacturing process to ensure that the quality of the final product is not compromised. Process validation studies should determine the length of time and temperature of the processing takes place (defining normal operational limits of the manufacturing process), and validate in-process hold times for product intermediates (including in-process freeze/thaw cycles).

Because the storage conditions for cryopreserved cardiovascular tissue are stated in this order (that is, at or below minus 100°C for no more than five years), validation of these storage conditions is not required. If storage conditions for non-cryopreserved cardiovascular tissue are implemented, full validation must be carried out.

Please note that in addition to TGO 109 requirements, all relevant requirements of TGO 107 (labelling of biologicals) apply to cardiovascular tissue. If further clarification is required, please contact TGA.

### Part 5 – Standard for human ocular tissue products

#### Section 31 – What this Part is about

|  |
| --- |
| **31 What this Part is about**  This Part specifies requirements that must be met in the manufacture of human ocular tissue products that have been subjected to only minimal manipulation and are manufactured for allogeneic use only, including requirements relating to human ocular tissue that is collected for use in the manufacture of those products.  Unless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part. |

Part 5 applies to biologicals that are human ocular tissue including the eye globe, cornea or sclera.

#### Section 32 – Application of this Part

|  |
| --- |
| **32 Application of this Part**  This Part applies in relation to human ocular tissue products that:   1. have been subjected to only minimal manipulation; and 2. are manufactured for allogeneic use only. |

Minimal manipulation is defined by TGA here:

* TGA guidance: [Method of preparation: Interpretation of minimal manipulation](https://www.tga.gov.au/sites/default/files/method-preparation-interpretation-minimal-manipulation.pdf)

Allogeneic use, in relation to an HCT product, means administration to, or application in the treatment of, a person other than the person from whom the HCT materials used in the manufacture of the product were collected.

#### Section 33 – Collection

|  |
| --- |
| **33 Collection**   1. Collection of human ocular tissue from a deceased donor must be completed not later than 48 hours after asystole, and the time intervals between asystole, enucleation, preservation and corneal excision must be documented. 2. A human ocular tissue product that is manufactured using human ocular tissue collected between 24 and 48 hours after asystole must not be released for supply unless: 3. a medical practitioner acting for, or on behalf of, the manufacturer or the sponsor has evaluated the quality, safety and efficacy of the product; and 4. the medical practitioner who is responsible for the administration to, or application in the treatment of, the recipient of the product has been notified that the collection occurred between 24 and 48 hours after asystole; and 5. the medical practitioners mentioned in paragraphs (a) and (b) are registered in a State or internal territory. |

Where ocular tissue is removed from the stated storage conditions to allow quality determination, for example, warmed to room temperature to optimise microscopic evaluation and/or endothelial cell counting, the process must be strictly defined and sound scientific justification provided as to why the quality and safety is not compromised.

#### Section 34 – Storage and transportation

|  |
| --- |
| **34 Storage and transportation**  Human ocular tissue products must be stored as follows:   1. in the case of an eye globe—in a moist chamber system at 0°C to 10°C for not more than 48 hours after collection of the eye globe; or 2. in the case of excised cornea—either: 3. in a corneal storage medium at 0°C to 10°C for not more than 14 days after collection of the cornea; or 4. in a storage medium at 28°C to 37°C for not more than 30 days after collection of the cornea; or 5. in a cryopreservation medium between minus 75°C to minus 196°C for not more than 2 years after the collection of the cornea; or 6. in the case of sclera—maintained in at least 75% v/v ethanol solution for not more than 1 year after collection of the sclera; or 7. in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products. |

Sponsors may be granted a shelf life for ocular products as outlined above. Validation of shelf life for packaging materials still needs to be performed by sponsors. The conditions of product storage should be specified to ensure maintenance of product quality, including the minimisation of microbial contamination.

#### Section 35 – Excised cornea – testing of storage medium etc.

|  |
| --- |
| **35 Excised cornea – testing of storage medium etc.**   1. Where excised cornea is stored in accordance with subparagraph 34(b)(ii), then: 2. the storage medium must be tested for microbial contamination using a validated test method prior to transfer of the tissue to a transport medium; and 3. subsequent exposure to the transport medium at a temperature validated to maintain tissue quality must not exceed 5 days. 4. If testing of the storage medium in accordance with paragraph (1)(a) demonstrates evidence of microbial contamination, then: 5. where the excised cornea has not been released for supply—the excised cornea must be rejected for therapeutic use; or 6. where the excised cornea has been released for supply—the results of the microbial tests must be reported to the medical practitioner who is responsible for the administration to, or application in the treatment of, the recipient of the product in accordance with the documented procedures of the manufacturer. |

This guidance only applies to excised cornea maintained in storage medium at 28-37°C for no more than 30 days.

All storage and transport solutions used in processing ocular tissue should be sterile.  
If the storage medium is intended to be sterile, then it should be tested and pass the harmonised test for sterility by the filtration method specified in the default standard pharmacopoeias. Validation of the test method is described as the ‘suitability of test’ and involves a demonstration of neutralisation of antimicrobial agents that might interfere with the growth of contaminants. Alternatively, the filtration method as described in the microbial contamination chapters of the pharmacopoeias should be validated to demonstrate the absence of growth in solutions not required to be sterile.

Unless the entire tissue product is subject to bioburden testing, it is necessary to validate that a sample or portion is representative of the entire tissue. During sampling validation studies, it is necessary to sample from a variety of areas across the tissue and to compare the bioburden test results. Routine bioburden samples should subsequently be taken from any area which represents the ‘worst case’ in terms of bioburden.

The microbial contamination sections of the pharmacopoeial default standards,[[11]](#footnote-11) as well as ISO/DTS 22456[[12]](#footnote-12) and ISO 14160,[[13]](#footnote-13) provide useful guidance on suitable bioburden test methods and their validation to demonstrate neutralisation/inactivation of antimicrobial substances. ISO 11737-1 specifically describes steps to establish the recovery efficiency and correction factor(s) to be applied when testing bioburden on or within solid and semi-solid starting materials.

Method validation involves challenging the method used for the material or product with low numbers (<100 CFU) of reference challenge microorganisms and recovering these organisms within the shortest test incubation time. Given that antimicrobial agents could be present in the starting materials and/or the end HCT product, it is necessary to attempt to neutralise these agents to optimise the recovery of the challenge microorganisms, and ultimately, any product contaminants. Pharmacopoeial and ISO methods mandate this step under ‘suitability of test method’ or ‘method validation’. Antimicrobial activity can often be removed by filtration, dilution and/or chemical inactivation through the use of a suitable neutralising agent. Tissue banks should attempt to identify antimicrobial agents used to treat donors and those agents used during processing in order to assist them to identify suitable neutralising agents. If antimicrobial properties cannot ultimately be neutralised, pharmacopoeias permit the product to be tested under the set of conditions established as optimal for recovery. This approach must be justified and details provided for assessment and/or audit by TGA.

#### Section 36 – Containers

|  |
| --- |
| **36 Containers**  A human ocular tissue product must be sealed within a sterile container and must be packaged so as to:   1. prevent ingress or egress of all materials; and 2. ensure that any breach of integrity of the container and packaging is evident. |

The sterile packaging should be compatible with the product and if terminally sterilised, with the method of sterilisation, for example, the packaging should allow the ingress of the sterilising agent and where applicable, its egress. It is permissible to sterilise the container along with the HCT. The use of new technology (for example, supercritical CO2) would be considered on a case-by-case basis based on evidence of validation to demonstrate that there is a maximal sterility assurance level (SAL) of 10-6 for a terminal sterilisation process. Guidance on novel sterilisation method validation can be found in ISO 14937.

If the tissue is aseptically manufactured, then it should be transferred into a sterile container and validated as an aseptic process (refer to ISO 13408 and ISO 18362).

#### Section 37 – Examination and evaluation

|  |
| --- |
| **37 Examination and evaluation**  Examination and evaluation of human ocular tissue must be in accordance with the requirements set out in section 10 of the EBAANZ Standards for Eye Donation and Eye Tissue Banking. |

The Eye Bank Association of Australia and New Zealand (EBAANZ) Medical and Quality Standards for Eye Donation and Eye Tissue Banking[[14]](#footnote-14) specifies the methods that should be used for the evaluation and examination of ocular tissue. This includes evaluation of the endothelial cells which must be documented for corneas.

Where ocular tissue is removed from the stated storage conditions to allow quality determination (for example, warmed to room temperature to optimise microscopic evaluation and/or endothelial cell counting), the process must be strictly defined with sound scientific justification provided as to why the quality and safety of the tissue is not compromised.

### Part 6­­ – Standard for human skin products

#### Section 38 – What this Part is about

|  |
| --- |
| **38 What this Part is about**  This Part specifies requirements that must be met in the manufacture of human skin products that have been subjected to only minimal manipulation, including requirements relating to human skin that is collected for use in the manufacture of those products.  Unless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part. |

Part 6 applies to biologicals that are human skin.

#### Section 39 – Application of this Part

|  |
| --- |
| **39 Application of this Part**  This Part applies in relation to human skin products that have been subjected to only minimal manipulation. |

Minimal manipulation is defined by TGA here:

* TGA guidance: [Method of preparation: Interpretation of minimal manipulation](https://www.tga.gov.au/sites/default/files/method-preparation-interpretation-minimal-manipulation.pdf)

#### Section 40 – Processing etc.

|  |
| --- |
| **40 Processing etc.**   1. Human skin must be sampled for bioburden testing following collection and prior to being packaged. 2. Processing of human skin must commence: 3. within 24 hours of collection; or 4. within a timeframe that is validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human skin product manufactured using the human skin. |

This section specifies the bioburden sampling and packaging requirements for collected skin. Both of these processes will require validation to demonstrate compliance with TGO 109.

Unless the entire tissue product is subject to bioburden testing, it is necessary to validate that a sample or portion is representative of the entire tissue. During sampling validation studies it is necessary to sample from a variety of areas across the tissue and to compare the bioburden test results. Routine bioburden samples should subsequently be taken from any area which represents the 'worst case' in terms of bioburden.

Tissue processing should commence within 24 hours of procurement. Before processing, the recovered skin should be kept in a temperature-controlled refrigerator at 2-8°C, without interruption throughout the refrigeration process. It is recommended that the cell nutrient medium used for viable grafts be changed shortly after receipt of skin grafts, or that the medium be validated for 24 hours storage (that is, adequate buffering capacity). All the manipulations where the transport containers are going to be exposed and the media changed must be performed in a controlled-air environment.

It should be noted that ‘commencement of processing’ is a broad term that may include the commencement of the bioburden reduction step in processing (addition of antimicrobial compounds) as required by Part 6.

#### Section 41 – Bioburden testing

|  |
| --- |
| **41 Bioburden testing**   1. Human skin sampled in accordance with subsection 40(1) must be tested for bioburden and, following that testing, must: 2. demonstrate no microbial contamination with specified microorganisms; or 3. be rejected for therapeutic use if microbial contamination with specified microorganisms is demonstrated. 4. If bioburden testing in accordance with subsection (1) demonstrates microbial contamination with microorganisms other than specified microorganisms, then the results of the testing must be reported by the manufacturer of the human skin product to the medical practitioner who is responsible for the administration to, or application in the treatment of, the recipient of the product. |

Bioburden sampling and testing must occur using validated techniques or testing methods.

Both the sampling method and the bioburden test method must be validated, the details of which should be included in the relevant section of the dossier. Unless the entire tissue product is subject to bioburden testing, it is necessary to validate that a sample or portion is representative of the entire tissue. During sampling validation studies, it is necessary to sample from a variety of areas across the tissue and to compare the bioburden test results. Routine bioburden samples should subsequently be taken from any area which represents the ‘worst case’ in terms of bioburden.

The microbial contamination sections of the pharmacopeial default standards, as well as ISO/DTS 22456 and ISO 14160, provide useful guidance on suitable bioburden test methods and their validation to demonstrate neutralisation/inactivation of antimicrobial substances. ISO 11737-1 specifically describes steps to establish the recovery efficiency and correction factor(s) that are to be applied when testing bioburden on/within solid and semi-solid starting materials (for example, bone, tendon). ISO 14160 Annex A.5.3 provides guidance on performing bioburden tests on animal tissues. Sponsors must develop a documented list with all relevant microorganisms that, if present, would result in a rejection of the product.

It is acknowledged that some starting materials are not sterile as they have inherent microflora that will not be eradicated by processing or manufacturing steps. The microbiological specifications for these finished products should be formulated to specify the maximum allowable level and specify the absence of ‘specified microorganisms’, which would render the product unsuitable for use

Normal microflora is to be expected in skin; in these instances, the treating physician should be informed if this is the case and alerted to the presence of any significant microbes. These microrganisms must not be named on the list of specified microorganisms preventing use of the tissue, but their identification allows the treating physician to make informed decisions regarding suitable antibiotic coverage for the recipient. The incubation and identification timeframes and the reporting procedure should be detailed in the appropriate dossier section.

#### Section 42 – Freeze-dried skin allografts

|  |
| --- |
| **42 Freeze dried skin allografts**  The residual moisture content of human skin products that are freeze‑dried must be less than 5%. |

The Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides) specifies a limit of ≤5% residual moisture for freeze dried skin allografts.

Processing of grafts by freeze-drying devitalises the grafts while maintaining their structure. A maximum limit for residual water content should be established and measured before release of the product, with the maximum level of residual moisture set at ≤ 5 %. Following freeze-drying, skin grafts can be stored at ambient temperature, with the stability of packaging validated for the proposed shelf life.

#### Section 43 – Storage and transport

|  |
| --- |
| **43 Storage and transport**  *Human skin*   1. Immediately following collection and prior to processing, human skin must be: 2. stored as follows: 3. at less than 10°C in a suitable storage medium; or 4. as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human skin product manufactured using the human skin; and 5. transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.   *Human skin products*   1. Human skin products must be stored as follows: 2. at less than minus 40°C for not more than 5 years after collection of the human skin; or 3. at 2°C to 8°C for not more than 14 days after collection of the human skin; or 4. if stored in greater than 75% glycerol solution—at 2°C to 8°C for not more than 2 years after the collection of the human skin; or 5. in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products. 6. Human skin products must be transported in a manner that ensures the relevant storage conditions specified in subsection (2) are maintained during transportation. |

This is adapted from best practice described in the Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides). This ensures that the collected skin tissue is transported and stored (before processing commences) in such a way as to maintain the quality of the allograft material, especially is the material will undergo minimal processing (viable skin allografts).

Immediately following procurement, the recovered tissue must be stored in a suitable transport medium in sterile, pre-labelled containers filled with appropriate transport medium. The containers must be sealed securely, refrigerated to 2-8°C, and transported to the processing facility as soon as possible. Transportation at low temperatures prevents proliferation of most bacteria and fungi, and maintains skin viability (if viable grafts are requested). Antibiotics can be added to the transport medium.

The proposed storage conditions and shelf life will be maintained in TGO 109. The conditions in in the former TGO for skin (TGO 86) were based on international best practice.

The specific post-processing skin storage and transport conditions detailed in this section are default storage times for skin processed and stored as detailed. If alternative storage conditions are specified by the manufacturer, validation will be required. The manufacturer must also demonstrate that the packaging and labelling are capable of maintaining integrity and critical quality attributes of the final product for the proposed shelf life.

Please note that in addition to TGO 109 requirements, all relevant requirements of TGO 107 (labelling of biologicals) apply to skin tissue. If further clarification is required, please contact TGA.

### Part 7 – Standard for human amnion products

#### Section 44 – What this Part is about

|  |
| --- |
| **44 What this Part is about**  This Part specifies requirements that must be met in the manufacture of human amnion products that have been subjected to only minimal manipulation, including requirements relating to human amnion that is collected for use in the manufacture of those products.  Unless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part. |

Part 7 applies to biologicals that are human amnion. These standards are new; previous biologicals TGOs did not have stand-alone requirements for amnion, but this is a product group which is seeing increased therapeutic advances. The establishment of a standard to ensure that amnion is manufactured to a minimum level would improve consistency of these therapeutic goods in Australia.

#### Section 45 – Application of this Part

|  |
| --- |
| **45 Application of this Part**  This Part applies in relation to human amnion products that have been subjected to only minimal manipulation. |

Minimal manipulation is defined by TGA here:

* TGA guidance: [Method of preparation: Interpretation of minimal manipulation](https://www.tga.gov.au/sites/default/files/method-preparation-interpretation-minimal-manipulation.pdf)

#### Section 46 – Collection

|  |
| --- |
| **46 Collection**   1. Human amnion used in the manufacture of human amnion products must be collected as soon as possible after caesarean section or vaginal delivery. 2. Processing of the human amnion must commence: 3. within 24 hours of collection; or 4. within a timeframe that is validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human amnion product manufactured using the human amnion. |

The Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides) states that vaginal delivery of amnion rather than collection via caesarean section in a surgical environment can introduce vaginal microflora to the starting tissue. For this reason, it is suggested that this tissue undergoes sterilisation following processing. As defined earlier in TGO 109, this will require validation of the irradiation process to meet a SAL of 10-6.

Immediate collection may be as soon as practicable after caesarean section or vaginal delivery. Donor placenta/fetal membranes should be procured by medical staff at obstetrics units after caesarean section. Amnion could be contaminated by normal vaginal flora during vaginal delivery; therefore, procurement under aseptic conditions after elective caesarean section is to be preferred. Staff undertaking procurement must be dressed appropriately for the procedure to minimise the risk of contamination of the procured tissue and any hazard to themselves. If procured during vaginal delivery, the processed product must be sterilised using a validated sterilisation method to achieve a SAL of 10-6 and ensure that any contaminating microflora is eliminated.

The Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides) recommends that processing commence as soon as possible after collection, with a maximum time of 24 hours. From collection to processing, storage in a suitable transport/decontamination medium is required to preserve the structural and biological properties of the amniotic membrane.

#### Section 47 – Terminal sterilisation

|  |
| --- |
| **47 Terminal sterilisation**  Human amnion products manufactured using human amnion collected following vaginal delivery must be terminally sterilised in accordance with section 14. |

If the product is to be terminally sterilised, then validation and routine control of sterilisation processes should be in accordance with the relevant parts of international sterilisation standards, for example, ISO 11135 (ethylene oxide), ISO 14937 (general methods), ISO 17665 (moist heat), ISO 11137 (radiation), ISO 14160 (chemical sterilisation), ISO 20857 (dry heat).

Some of these standards are relevant to the sterilisation of containers and ancillary materials used during tissue processing.

All containers should be sterile and any of the ISO standards listed above provide guidance for validating the relevant sterilisation process for containers. Containers can also be pre-purchased as sterile.

#### Section 48 – Dehydrated products

|  |
| --- |
| **48 Dehydrated products**  The residual moisture content of human amnion products that are dehydrated must be less than 15%. |

To ensure stability of the dried product, maximum levels of residual moisture must be mandated to prevent degradation of the product and the proliferation of any residual microorganisms. This level of residual moisture is that for current dehydrated products in the ARTG.

Dehydrated amnion membranes may be conducted at ambient or elevated temperatures (up to 40°C) which generally induce little change in tissue properties. The processed membrane is placed on support structures before being exposed to air until a final water content of ≤15% is achieved. Following packaging, the product can be stored at room temperature.

Residual moisture should be determined for each batch of amnion using a sample that has undergone the same drying protocol (a release test). Alternatively, the drying process may be validated to demonstrate process consistency.

#### Section 49 – Freeze-dried products

|  |
| --- |
| **49 Freeze-dried products**  The residual moisture content of human amnion products that are freeze‑dried must be less than 10%. |

This clause is based on recommendations in the Council of Europe’s [4th Edition of the Guide to the quality and safety of tissues and cells for human application (2019)](https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides). Dried amnion must meet minimum levels of residual moisture to ensure stability of the product during proposed shelf life.

Freeze-drying amnion induces minimal changes in tissue properties. The processed membrane is rapidly frozen and then vacuum-dried using a freeze-drying device. Water from the tissue is extracted through sublimation until a final water content of ≤10% is achieved. Following packaging, the product can be stored at room temperature.

Residual moisture should be determined for each batch of amnion using a sample that has undergone the same drying protocol (a release test). Alternatively, the drying process may be validated to demonstrate process consistency.

#### Section 50 – Storage and transportation

|  |
| --- |
| **50 Storage and transportation**  *Human amnion*   1. Immediately following collection and prior to processing, a human amnion must be: 2. stored at less than 10°C in a suitable storage medium, or as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality and safety of the human amnion; and 3. transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.   *Human amnion products*   1. Human amnion products must be stored as follows: 2. if the products are cryopreserved—at less than minus 80°C for not more than 2 years after collection of the human amnion; or 3. if the products are dehydrated or freeze-dried—at room temperature for not more than 5 years after collection of the human amnion; or 4. in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products. 5. Human amnion products must be transported in a manner that ensures the relevant storage conditions specified in subsection (2) are maintained during transportation. |

The storage and transport time of procured placenta/foetal membranes should be kept as short as possible (the recommended maximum time is 24 hours) and a temperature of 2-8°C should be maintained. Procured placenta/foetal membranes should be placed in a sterile receptacle containing a suitable transport medium or decontamination solution. The manufacturer should validate the composition of the transport medium and determine if antibiotics are required. The temperature during transport to the manufacturing site must be maintained. Temperature stability should be guaranteed by the container, conditions of transport used, and for the time interval before processing. It should be noted that ‘processing’ may include steps such as treatment with decontamination or antimicrobial solutions during transportation.

Part 7 allows for alternatives to the specified shelf life if the manufacturer is able to provide specific validation data for their product.

The manufacturer must also demonstrate that the packaging and labelling are capable of maintaining integrity and critical quality attributes of the final product for the proposed shelf life. If the product release specifications include additional criteria linked to the product’s intended use (for example, the presence of growth factors or cytokines), the manufacturer must validate that the product meets the release specifications at the end of the proposed shelf life.

Please note that in addition to TGO 109 requirements, all relevant requirements of TGO 107 (labelling of biologicals) apply to amnion. If further clarification is required, please contact TGA.

Version history

| Version | Description of change | Author | Effective date |
| --- | --- | --- | --- |
| V1.0 | Original publication  Replaces:  ARGB Appendix 5 – Guidance on TGO 85  ARGB Appendix 6 – Guidance on TGO 83  ARGB Appendix 7 – Guidance on TGO 84  ARGB Appendix 8 – Guidance on TGO 86 | Biological Science Section, Scientific Evaluation Branch | May 2021 |

|  |
| --- |
| Therapeutic Goods Administration |
| PO Box 100 Woden ACT 2606 Australia  Email: [info@tga.gov.au](mailto:info@tga.gov.au) Phone: 1800 020 653 Fax: 02 6203 1605  [**https://www.tga.gov.au**](https://www.tga.gov.au) |
| Reference/Publication # |

1. British Pharmacopoiea, European Pharmacopoeia, United States Pharmacopeia. See also TGO 77 (applies to medicines) for section references. [↑](#footnote-ref-1)
2. ISO/DTS 22456 Sterilization of healthcare products — Microbiological Methods—Guidance on conducting bioburden determinations and tests of sterility for tissue-based Products. [↑](#footnote-ref-2)
3. ISO 14160 Sterilization of health care products -Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives - Requirements for characterization, development, validation and routine control of a sterilization process for medical devices. [↑](#footnote-ref-3)
4. From the 4th edition; see Chapter 18, Table 18.2 for amniotic membrane; Chapter 19, Table 19.2 for skin; Chapter 20, Table 20.3 for cardiovascular tissue; Chapter 21, Table 21.2 for musculoskeletal tissue. [↑](#footnote-ref-4)
5. British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopeia. See also TGO 77 (applies to medicines) for section references. [↑](#footnote-ref-5)
6. ISO/DTS 22456 Sterilization of healthcare products – Microbiological Methods – Guidance on conducting bioburden determinations and tests of sterility for tissue-based Products. [↑](#footnote-ref-6)
7. ISO 14160 Sterilization of health care products – Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives – Requirements for characterization, development, validation and routine control of a sterilization process for medical devices. [↑](#footnote-ref-7)
8. British Pharmacopoiea, European Pharmacopoeia, United States Pharmacopeia. See also TGO 77 (applies to medicines) for section references. [↑](#footnote-ref-8)
9. ISO/DTS 22456 Sterilization of healthcare products — Microbiological Methods—Guidance on conducting bioburden determinations and tests of sterility for tissue-based Products. [↑](#footnote-ref-9)
10. ISO 14160 Sterilization of health care products -Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives - Requirements for characterization, development, validation and routine control of a sterilization process for medical devices. [↑](#footnote-ref-10)
11. British Pharmacopoiea, European Pharmacopoeia, United States Pharmacopeia (Also see TGO 77 for medicines for section refs). [↑](#footnote-ref-11)
12. ISO/DTS 22456 Sterilization of healthcare products — Microbiological Methods—Guidance on conducting bioburden determinations and tests of sterility for tissue-based Products. [↑](#footnote-ref-12)
13. ISO 14160 Sterilization of health care products -Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives - Requirements for characterization, development, validation and routine control of a sterilization process for medical devices. [↑](#footnote-ref-13)
14. Edition 2, April 2009, Chapter 10. [↑](#footnote-ref-14)